Pandemic Like Never Before – Continuous Manufacturing to the Rescue
Roots Analysis
by Ankita Kashyap
2d ago
The coronavirus outbreak and the drop in economy that we are facing today is unlike anything that most of us have seen in our lifetime. The pandemic has threatened the whole world to such an extent that life has come to a standstill. In fact, the initial stage of lockdown featured the fragile nature of pharmaceutical supply chain as a result of plant shutdowns and subsequent drug shortages. However, in order to deal with this situation, the medical agencies came up with the option of advanced technologies, such as continuous manufacturing technology. Specifically, in the pharmaceutical industr ..read more
Visit website
Antiviral Medications: An Unmet Requirement in Pharmaceuticals
Roots Analysis
by Arun Gupta
2w ago
Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral medications (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life threatening infectious diseases in hu ..read more
Visit website
MRNA Technology: Transforming Medicine
Roots Analysis
by Simran Kaur
2w ago
Messenger ribonucleic acid (mRNA) serves as a carrier of genetic instructions from DNA to the cell machinery for the production of proteins. mRNA technology plays a significant role in the development of therapeutic interventions, exemplified by the incredible success of COVID-19 vaccines (namely COMIRNATY and Spikevax). It holds promise in treating various autoimmune disorders, degenerative disorders, genetic disorders, metabolic disorders, infectious diseases and oncological disorders. Further, mRNA therapeutics offer advantages (over traditional small molecules) such as simpler design, shor ..read more
Visit website
Anti-Counterfeiting Technologies in Healthcare
Roots Analysis
by Arun Gupta
1M ago
In order to effectively combat the problems related to counterfeit medicines, several companies have come up with innovative technologies to provide the necessary tools to manufacturers, healthcare professionals and patients to authenticate pharmaceutical products. Anti-counterfeiting technologies technologies can be broadly classified under two categories, namely Authentication Technologies and Track & Trace Technologies. Authentication technologies are further sub-categorized into technologies that provide Overt security features and those that offer Covert features. Each category has it ..read more
Visit website
Zealand Pharma Stock Surge on Liver Disease Drug Trial Data
Roots Analysis
by Pemba Lahmo
1M ago
Shares of Zealand Pharma experienced a significant surge, jumping 16% as the market opened on Monday, following the release of groundbreaking phase II trial results for an experimental obesity treatment being developed in collaboration with Boehringer Ingelheim. This surge came as the trial testing the drug survodutide for the treatment of fatty liver, specifically metabolic dysfunction-associated steatohepatitis (MASH), yielded highly promising outcomes. The trial, conducted by Boehringer Ingelheim, revealed that up to 83.0% of adults treated with survodutide achieved a statistically signifi ..read more
Visit website
ADCs Pipeline Update: Sutro Biopharma Presents Encouraging Data in Patients with Advanced Ovarian Cancer
Roots Analysis
by Gaurav Chaudhary
1M ago
Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models. Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology ..read more
Visit website
COVID-19 and Recession: How Big will be the Impact?
Roots Analysis
by Gaurav Chaudhary
1M ago
In a blog posted a few weeks ago, I talked about the key strategies that the pharma companies can adopt to deal with the impact of COVID-19 and Recession. The strategies were dependent on the position of the companies on the recession readiness evaluation framework (added below). Check out the blog for more details on this. Two of the key parameters that have a prominent impact on the strategy are the length of the recession and the depth of the recession. In this article, we will be looking at the historical recession data to try and assess these two parameters. Historical Recession Data: Du ..read more
Visit website
CARsgen anti-BCMA CAR T CellTherapy Receives RMAT Designation
Roots Analysis
by Gaurav Chaudhary
1M ago
On 28 October 2019, CARsgen Therapeutics, a clinical-stage biopharma company, announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. What is CT-053: CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple myeloma. What is RMAT designation:  Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and ..read more
Visit website
COVID-19 and Recession: Identifying Long-Term Growth Opportunities
Roots Analysis
by Gaurav Chaudhary
1M ago
Well before the COVID-19 and Recession pandemic, there were warning signs of an imminent US recession. The ongoing pandemic, and trade conflicts between the US. and China, and the US and Europe have just accelerated the fall of the global economy. In fact, as per the United Nations, the world economy is expected to go into recession this year with a predicted loss of trillions of dollars of global income. This is expected to create immense problems across developing countries with the likely exception of India and China. Is the Pharmaceutical Industry Recession-Proof? In absolute terms, no ind ..read more
Visit website
Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy
Roots Analysis
by Gaurav Chaudhary
1M ago
Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. The global genome editing market is anticipated to grow at a CAGR of 12.6% during the forecast period 2023-2035. Get a complete list of the presentations, here. How is the genome editing market landscape evolving: Currently, there is ..read more
Visit website

Follow Roots Analysis on FeedSpot

Continue with Google
Continue with Apple
OR